15 completed, 5 terminated, 4 active not recruiting, 2 unknown. 17 Phase 1, 12 Phase 2, 1 Not applicable, 1 Phase 3.
Follow Innate Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors IPH4502 - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Innate Pharma | 145 | 2025-01-24 | 2026-07-27 |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma IPH6501 - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Innate Pharma | 23 | 2024-03-04 | 2026-04-14 |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) IPH5201 + durvalumab + standard chemotherapy - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Innate Pharma | 70 | 2023-06-23 | 2026-06-17 |
| Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 lacutamab - Peripheral T Cell Lymphoma | Phase 1 | Completed | Innate Pharma | 20 | 2022-03-17 | 2024-03-28 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB - Metastatic Cancer, Metastatic Breast Cancer | Phase 1 | Active not recruiting | Institut Paoli-Calmettes | 27 | 2022-01-21 | 2026-06-22 |
| Study of Lacutamab in Peripheral T-cell Lymphoma Lacutamab, Gemcitabine, Oxaliplatine - Peripheral T Cell Lymphoma, Relapse/Recurrence | Phase 2 | Active not recruiting | The Lymphoma Academic Research Organisation | 49 | 2021-10-05 | 2026-06-04 |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer Monalizumab, Cetuximab, Placebo - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Active not recruiting | AstraZeneca | 370 | 2020-10-02 | 2026-09-09 |
| Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) avdoralimab, Placebo - COVID | Phase 2 | Completed | Assistance Publique Hopitaux De Marseille | 208 | 2020-04-27 | 2021-05-27 |
| C5a Receptor Expression - COVID-19 (C5-COV) draw blood - COVID-19 | Not applicable | Completed | Assistance Publique Hopitaux De Marseille | 61 | 2020-03-31 | 2023-08-14 |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma IPH4102 - Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous | Phase 2 | Completed | Innate Pharma | 170 | 2019-05-22 | 2026-04-29 |
| IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors IPH5401 and Durvalumab - Advanced Solid Tumors | Phase 1 | Terminated | Innate Pharma | 73 | 2018-09-07 | 2022-01-27 |
| Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA Monalizumab, Oxaliplatin, 5-Fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Jules Bordet Institute | 2017-07-20 | 2017-12-19 | |
| Immunological Profile of Solid Tumors Sample immunohistochemistry assay - Solid Cancer | Unknown | Assistance Publique Hopitaux De Marseille | 1040 | 2017-04-06 | 2018-01-30 | |
| Study of the Immune Response in Colon Adenocarcinoma Colon Adenocarcinoma | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 100 | 2017-02-05 | 2025-12-10 | |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation Monalizumab - Hematologic Malignancies | Phase 1 | Unknown | Institut Paoli-Calmettes | 18 | 2016-11-28 | 2018-09-19 |
| Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Monalizumab, Cetuximab, Anti-PD(L)1 - Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | Innate Pharma | 143 | 2015-12-01 | 2023-05-12 |
| Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL monalizumab - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | Innate Pharma | 22 | 2015-11-09 | 2019-12-17 |
| Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) IPH4102 - Cutaneous T-Cell Lymphoma | Phase 1 | Completed | Innate Pharma | 44 | 2015-10-01 | 2021-01-20 |
| A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies IPH2201 - Gynecologic Cancer | Phase 1 | Completed | Canadian Cancer Trials Group | 59 | 2015-09-17 | 2023-08-04 |
| Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity IPH2201, Standard Surgery, Postsurgical Adjuvant Therapy - Squamous Cell Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Terminated | Innate Pharma | 3 | 2014-12-01 | 2017-01-04 |
Showing 20 of 28. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Squamous Cell Carcinoma (2) · Head and Neck Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Cutaneous (2) · Lymphoma, T-Cell, Peripheral (2) · Multiple Myeloma (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · COVID-19 (1)
monalizumab (5) · IPH-2101 (4) · Cetuximab (2) · Drug Therapy (2) · Oxaliplatin (2) · avdoralimab (2) · durvalumab (2) · Carboplatin (1) · Fluorouracil (1) · Gemcitabine (1) · Metabolic Networks and Pathways (1) · Pemetrexed (1) · Saline Solution (1) · Surgical Procedures, Operative (1) · Trastuzumab (1)
France (19) · United States (13) · Germany (5) · Belgium (4) · Spain (4) · Poland (3) · Australia (2) · Austria (2) · Canada (2) · Greece (2) · Italy (2) · Netherlands (2) · South Korea (2) · United Kingdom (2) · Argentina (1)
Norbert Vey, MD (2) · Amelie Deleporte, Physician (1) · Anna Tinker (1) · Dario Ruscica, MD (1) · Don Benson, Jr., MD, PhD (1) · Don Benson, MD (1) · Emilie Garrido-Pradalie (1) · Hal Hirte (1)
PMID 23033266, PMID 25999435, PMID 29700172, PMID 30871626, PMID 31253572, PMID 31308062, PMID 34473343, PMID 35687761, PMID 35803702, PMID 36218354, PMID 36852723, PMID 41151963
2014 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1)